卒中合并心外上动脉粥样硬化患者的抗栓治疗
该系统评价与荟萃分析检索PubMed和Scopus至2019年8月28日,纳入10项随机对照试验共6068例卒中/TIA合并心外上动脉粥样硬化患者,比较口服抗凝药与抗血小板药。结果显示抗凝治疗未降低复发性缺血性卒中风险(RR 0.91,95%CI 0.70-1.18),但大出血风险增加(RR 3.21,95%CI 1.96-5.24)。
要点
- 抗凝与抗血小板在复发性缺血性卒中风险上无显著差异
- 抗凝治疗大出血风险是抗血小板的3.21倍
- 主要缺血事件或死亡风险两组相似
核心结论
- 在卒中合并心外上动脉粥样硬化患者中,抗凝治疗与抗血小板治疗相比复发性缺血性卒中风险无差异,但大出血风险显著增加。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed和Scopus至2019年8月28日,纳入10项随机对照试验共6068例卒中/TIA合并心外上动脉粥样硬化患者。
主要发现
- 复发性缺血性卒中率抗凝组2.94/100患者年 vs 抗血小板组3.30/100患者年(RR 0.91,95%CI 0.70-1.18,I2=26%)。
- 主要缺血事件或死亡率抗凝组4.39/100患者年 vs 抗血小板组4.32/100患者年(RR 1.03,95%CI 0.79-1.35,I2=54.5%)。
- 大出血率抗凝组2.88/100患者年 vs 抗血小板组0.82/100患者年(RR 3.21,95%CI 1.96-5.24,I2=46%)。
关键数值与推荐
- 复发性缺血性卒中RR 0.91(95%CI 0.70-1.18)。
- 主要缺血事件或死亡RR 1.03(95%CI 0.79-1.35)。
- 大出血RR 3.21(95%CI 1.96-5.24)。
临床怎么用
- 对于卒中合并心外上动脉粥样硬化患者,抗凝治疗不优于抗血小板治疗,且大出血风险更高,应优先考虑抗血小板治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of oral anticoagulants vs antiplatelets in patients with stroke and atherosclerotic plaques in the aortic arch or cervical or intracranial arteries, collectively described as supracardiac atherosclerosis. METHODS: We searched PubMed and Scopus until August 28, 2019, for randomized trials comparing oral anticoagulants vs antiplatelets in patients with stroke and supracardiac atherosclerosis using the terms "anticoagulant or anticoagulation" and "antiplatelet or aspirin" and "randomized controlled trial or RCT" and "stroke or cerebral ischemia" and "aortic or carotid or vertebrobasilar or intracranial or atherosclerosis or stenosis or arterial." Four outcomes were assessed: recurrent ischemic stroke, major ischemic event or death, major bleeding, and intracranial bleeding. Treatment effects (relative risk [RR] and 95% confidence interval [CI]) were estimated by meta-analysis using random-effects models. RESULTS: Among 1,117 articles identified in the literature search, results from 10 randomized controlled trials involving 6,068 patients with stroke/TIA with supracardiac atherosclerosis were included in the meta-analysis. Recurrent ischemic stroke rates were 2.94 per 100 patient-years in the anticoagulant-assigned patients vs 3.30 per 100 patient-years in the antiplatelet-assigned patients (RR, 0.91; 95% CI, 0.70-1.18 for the SJ estimator, I2 = 26%). Major ischemic event or death rates were 4.39 per 100 patient-years in anticoagulant-assigned patients vs 4.32 in antiplatelet-assigned patients (RR, 1.03; 95% CI, 0.79-1.35; I2 = 54.5%). Major bleeding rates were 2.88 per 100 patient-years in anticoagulant-assigned patients vs 0.82 in antiplatelet-assigned patients (RR, 3.21; 95% CI, 1.96-5.24; I2 = 46%). CONCLUSION: This systematic review and meta-analysis showed that anticoagulant-assigned patients with stroke and supracardiac atherosclerosis were not at different risk of ischemic stroke recurrence and increased risk of major bleeding compared to antiplatelet-assigned patients.
引用
- Sagris D, Georgiopoulos G, Leventis I, et al. Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. Neurology. 2020. PMID: 32631920. doi:10.1212/WNL.0000000000009823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。